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Understanding a tumor’s complex cellular heterogeneity
will be crucial for the development of better treatment
strategies. A new study suggests a novel method for
the in silico dissociation of solid tumors and presents
novel insights that have implications for immunotherapy
in cancer.transformed cancer cells in the tumor sample. TumorCellular heterogeneity of solid tumors
Traditionally, anti-cancer therapies have exclusively tar-
geted malignant cancer cells. More recently, tumors are
increasingly seen not just as a mass of proliferating cells
but as a complex milieu of factors that promote and in-
hibit growth, as well as nutrients, chemokines, and, very
importantly, other non-cancerous cell types. The cancer
immunotherapy field has seen significant progress in tar-
geting tumor-infiltrating lymphocytes (TILs) during the
past decade. TILs are among a variety of innate and
adaptive immune cells that interact with the malignant
cancer cells to form a dynamic environment, in which
they act to both promote and inhibit tumor growth, in-
vasion, and metastasis [1]. A better understanding of the
cellular heterogeneity of the tumor and of the interac-
tions between the tumor and its microenvironment is
crucial for improving existing treatments, for the discov-
ery of predictive biomarkers, and for the development of
novel therapeutic strategies.
The Cancer Genome Atlas (TCGA) provides us with
the opportunity to study multiple “omics” characteriza-
tions of thousands of tumors across tens of cancer types
and to associate these characterizations with clinical in-
formation from the patients [2]. This profoundly import-
ant dataset, which is open and accessible, has given rise
to a surge in new knowledge about cancer. The cancer* Correspondence: atul.butte@ucsf.edu
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dataset in developing methods that can accurately infer
the heterogeneity and the components of the tumor
microenvironment. Unfortunately, the high cellular and
mutational heterogeneity of tumors make this a difficult
problem to tackle. A simpler undertaking is to consider
all the non-malignant cells in the tumor as a whole or,
conversely, to estimate tumor purity—the percentage of
purity can be inferred successfully by utilizing different
types of measurements that are available in TCGA, such
as copy number, transcriptional and DNA methylation
landscapes, and also the actual available image slides. In
a recent study, we demonstrated how even such a crude
measure has an immense effect on genomic reasoning
[3]. Thus, it is clear that studies of genomic data require
the ability to resolve the tumor’s cellular heterogeneity.
Deeper evaluation of the composition of cells in a tumor
requires more complex and sophisticated methods that
are associated with greater uncertainty.
Computational methods for resolving a tumor’s
cellular composition
In the past decade, many computational methods have
been applied in an attempt to gain better insight into the
cellular heterogeneity of bulk tumors (reviewed in [4]).
Generally, these methods attempt to associate “refer-
ence” gene sets that have been learned from purified im-
mune cell types with transcriptomic profiles. Several
such methods look for the enrichment of gene signa-
tures that are associated with these individual cell types.
The most challenging problem is inferring the complete
cellular composition of admixed transcriptomes, and
several deconvolution techniques have been applied in
an attempt to tackle this problem. A recent approach for
enumerating cell proportions named CIBERSORT pro-
vided estimations for 22 immune subsets [5] and has
since been widely applied to an array of cancer types.
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date, these methods have been limited to microarray
studies and thus are not directly applicable to TCGA.
To address this issue, Liu and colleagues combined de-
convolution strategies with estimations of tumor purity
and presented TIMER: Tumor-IMmune Estimation Re-
source, a novel method for estimating the proportions of
tumor–immune infiltrating subsets [6]. In this method,
tumor purity estimations are used to find and filter
genes that are associated with immune infiltration, and
deconvolution is then applied with improved certainty.
To apply TIMER on TCGA samples, Liu and colleagues
applied a method to remove “batch effects” on the signa-
ture matrix to allow direct estimation of the abundance
of certain cell types. Importantly, to gain better accuracy,
the authors followed the “less is more” philosophy,
choosing to focus on six major immune cell subsets that
are strongly distinguishable rather than on more cell
types. Liu and colleagues assert that by including more
immune cell types into the regression, CIBERSORT in-
ference suffers from a statistical co-linearity that results
in biased estimations.
Application to immunotherapy treatments
Immunotherapy treatments have already helped vast
numbers of patients who have cancers, such as melan-
oma and renal cell carcinoma, for whom traditional
therapies have failed. Furthermore, ongoing studies sug-
gest that these therapies may benefit patients who have
many additional types of cancer, including lung, brain,
head and neck, and stomach cancers [7]. Nevertheless,
we do not yet know why immunotherapy is effective in
some patients but not in others. Thus, there is a pressing
need to develop better tools to distinguish patients who
respond to cancer immunotherapy from those who do
not. Careful examination of the associations between
TIMER estimates and the known immunotherapy targets
allowed Liu and colleagues to make interesting observa-
tions and to suggest novel targets for cancer vaccines.
The authors found correlations between CD8+ T-cell
levels and known cancer/testis antigens such as
MAGEA3, which have been put forward as effective can-
cer vaccine targets. On the basis of this observation, they
further suggested a novel target, SPAG5, as a potential
vaccine target for multiple cancers. Another observation
relates to CTLA-4 expression and CD8+ T-cell abun-
dance. CTLA-4 is known to be expressed exclusively by
T cells. There is an association between both CTLA-4
expression and elevated CD8+ T cells and better clinical
response to anti-CTLA-4 treatment, but this association
is relatively weak. In this study, the authors reported that
a group of melanoma and renal cancer patients who had
low CD8+ T cells unexpectedly expressed high levels of
CTLA-4. This result may explain the varied clinicalresponse to checkpoint blockade therapies, newer treat-
ments that have no underlying anti-tumor effect but in-
stead remove inhibition on immune cells targeting the
cancer. Another immune checkpoint blockade gene,
TIM3, showed a pattern of expression that was inversely
related to T-cell numbers, a finding that was further val-
idated by staining renal tumors, which showed its ex-
pression in cancer cells. The TIMER estimates are
provided as a web resource to allow cancer immunolo-
gists to further explore the cancer–immune cell interac-
tions (http://cistrome.org/TIMER).
The road ahead
Characterization of the cellular composition of solid tis-
sues was traditionally performed using flow cytometry-
based methods. These are potent tools for immunology
research and for monitoring changes in immune-cell
quantities, but they require tissue destruction, thereby
affecting cellular state, integrity, and accuracy. Another
disadvantage of single-cell methods is the need to per-
form the analysis on fresh tissues, which requires a sup-
porting operational system and does not allow the
association of findings with known clinical outcomes.
Thus, the emerging use of single-cell RNA sequencing
will not yet allow us to profile the cellular composition
of solid tissues accurately. Hence, computational algo-
rithms that are used to deconvolve bulk transcriptomic
profiles will continue to offer a parallel and powerful ap-
proach that makes it possible to infer changes in cell
quantities from data describing gene expression in com-
plex tissues. In silico tissue dissection can be performed
on frozen and fixed tumor specimens, does not rely on
single-cell suspension, and, most importantly, can be
applied immediately to thousands of publicly available
tumor samples.
While computational methods provide many advan-
tages, they should be scrutinized carefully. All methods
to date are based on reference transcriptomic profiles of
pure immune cell types, which are used to infer the be-
havior of these cell types in admixtures. It is unclear if
this is a valid hypothesis. For example, while a particular
gene may be specific to one cell type and therefore will
be assigned as a reference gene, the number of mRNA
copies of that gene may vary significantly depending on
the state of the tissue. In tumors, another layer of uncer-
tainty is added to the modeling. In a recent study, we
have shown that the cancer cells themselves may express
notable inflammatory response genes, thus producing a
pattern of expression that resembles that resulting from
the infiltration of macrophages [8].
It is clear that current methods cannot yet capture the
full cellular heterogeneity in tumors. Newer measure-
ments using molecular imaging could provide the re-
search community with better measurements from
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culating free DNA and RNA might allow estimations of
what is going on inside cancer cells. We envision that
methods that can integrate information from comple-
mentary datasets—including imaging methods, genetic,
epigenetic, transcriptomic and proteomics profiles, and
immune repertoire profiles both of the bulk tumor and
from single-cell analyses—will lead to comprehensive
portrayal of tumors. In turn, we expect that this will
lead to better treatment strategies and ultimately to bet-
ter prognosis for patients.
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